ASCO 2026
Samuel J. Klempner, MD, FASCO, on Advanced HER2-Negative Gastroesophageal Cancer: Ivonescimab Plus FOLFOX
Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluat...
Peter Schmid, MD, PhD, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Giredestrant by Menopausal Status
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patie...
Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ...
John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in...
Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective
Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation ther...
Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide
Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ ...
Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone recepto...
Julie R. Gralow, MD, FACP, FASCO, on Highlights of the 2026 ASCO Annual Meeting
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included i...
Brian M. Wolpin, MD, MPH, and Eileen M. O’Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluate...
Jonathan W. Goldman, MD, on RET Fusion–Positive NSCLC: Adjuvant Selpercatinib
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy ...
Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial
Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus and...
Lillian L. Siu, MD, on Liquid KRAS Mutation Screening in Patients With Advanced Pancreatic Cancer
Lillian L. Siu, MD, of Princess Margaret Cancer Centre, discusses the clinical utility of liquid biopsy testing for common KRAS variants to facilitate matching patients with pancreatic ductal adenocar...
Veronica Diermayr, PhD, on AI-Driven Prediction of N256-Glycosylated CEACAM5/6 Expression in Gastric and Esophageal Cancer
Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of...
Evan T. Hall, MD, on Merkel Cell Carcinoma: Tuvusertib With or Without Avelumab
Evan T. Hall, MD, of Fred Hutchinson Cancer Center, discusses findings from the randomized phase II MATRiX trial, which evaluated the efficacy of the ATR inhibitor tuvusertib with or without avelumab ...
Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC
Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients ...
Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhi...
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III All...
Manali Kamdar, MD, on Rapid Oral Abstract Highlights: Three Emerging Trends in Lymphoma Care
Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell ...
Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03
Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in t...
Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC
Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radi...
Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC
Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the an...
Tony S.K. Mok, MD, FRCPC, FASCO, on Advanced ALK-Positive NSCLC: 7-Year Update From the CROWN Trial
Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positi...
Atish Choudhury, MD, PhD: Can Patients With an Exceptional Response to ARPIs Interrupt ADT?
Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interrupt...
Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL
Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination wi...
Ramez N. Eskander, MD, on Endometrial Cancer: Pembrolizumab Plus Carboplatin/Paclitaxel
Ramez N. Eskander, MD, of UC San Diego Moores Cancer Center, presents an updated overall survival analysis and examination of subsequent therapy in patients with endometrial cancer treated with pembro...
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer ...
Behind the Scenes of the 2026 ASCO Annual Meeting
The ASCO Annual Meeting is one of the largest and most impactful oncology conferences of the year, featuring practice-changing data, state-of-the-art updates, developmental therapeutics, global issues...
Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer
Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to res...
GLP-1 Receptor Agonists May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findin...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention program named Yoga for Cancer Survivors (YOCAS) improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase...
Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer
Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results of a...
Losing Weight, Gaining Quality of Life in Early-Stage Breast Cancer
A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings fr...
